-
1.发明授权Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry 失效通过施用受控化学的抗原的寡聚形式来治疗性抑制特异性免疫应答
公开(公告)号：US6022544A
公开(公告)日：2000-02-08
申请号：US391267
申请日：1995-02-21
申请人： Howard M. Dintzis , Renee Z. Dintzis , James K. Blodgett , John C. Cheronis , Gary Kirschenheuter
发明人： Howard M. Dintzis , Renee Z. Dintzis , James K. Blodgett , John C. Cheronis , Gary Kirschenheuter
CPC分类号： B82Y5/00 , A61K39/0008 , A61K47/48176 , A61K47/48284 , A61K47/48969 , A61K2039/6093
摘要： The invention features a method for reducing an undesired antibody response in a mammal by administering to the mammal a non-immunogenic construct which is free of high molecular weight immunostimulatory molecules. The construct which contains at least two copies of a B cell membrane immunoglobulin receptor epitope bound to a pharmaceutically acceptable non-immunogenic carrier directly binds to B cell membrane immunoglobulin receptors but fails to form an immunon.
摘要翻译： 本发明的特征在于通过向哺乳动物施用不含高分子量免疫刺激分子的非免疫原性构建体来减少哺乳动物中不需要的抗体应答的方法。 含有与药学上可接受的非免疫原载体结合的B细胞膜免疫球蛋白受体表位的至少两个拷贝的构建体直接结合B细胞膜免疫球蛋白受体，但不能形成免疫。
-
2.发明授权Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry 失效通过施用受控化学的抗原的寡聚形式来治疗性地抑制特异性免疫应答公开(公告)号：US06375951B1
公开(公告)日：2002-04-23
申请号：US08440331
申请日：1995-05-12
申请人： Howard M. Dintzis , Renée Z. Dintzis , James K. Blodgett , John C. Cheronis , Gary Kirschenheuter
发明人： Howard M. Dintzis , Renée Z. Dintzis , James K. Blodgett , John C. Cheronis , Gary Kirschenheuter
IPC分类号： A61K3900
CPC分类号： B82Y5/00 , A61K39/0008 , A61K47/58 , A61K47/643 , A61K47/6951 , A61K2039/6093
摘要： The invention features a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen. The construct is free of high molecular weight immunostimulatory molecules and contains copies of the epitope which bind to a B cell membrane immunoglobulin receptor specific for the epitope but fail to form an imnunon.
摘要翻译： 本发明的特征在于用于减少对T依赖性抗原的表位的非一级抗体应答的非免疫原性构建体。 该构建体没有高分子量的免疫刺激分子，并且含有与表位特异性但不能形成亚硝酸盐的B细胞膜免疫球蛋白受体结合的表位的拷贝。
-
3.发明授权Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry 失效通过施用受控化学的抗原的寡聚形式来治疗性地抑制特异性免疫应答公开(公告)号：US06340460B1
公开(公告)日：2002-01-22
申请号：US08440322
申请日：1995-05-12
IPC分类号： A61K3900
CPC分类号： B82Y5/00 , A61K39/0008 , A61K47/58 , A61K47/643 , A61K47/6951 , A61K2039/6093
摘要： A method of making a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen by coupling two or more copies of the epitope to a nonimmunogenic soluble carrier to yield a conjugate preparation and removing high molecular weight immunostimulatory molecules.
摘要翻译： 通过将两个或更多拷贝的表位偶联至非免疫原性可溶性载体来制备非免疫原性构建体以减少对T依赖性抗原的表位的非一级抗体应答的方法，以产生缀合物制剂并除去高分子量 免疫刺激分子。
-
4.发明授权Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. 失效通过施用抗原竞争结合物治疗性抑制特异性免疫应答。
公开(公告)号：US5126131A
公开(公告)日：1992-06-30
申请号：US248293
申请日：1988-09-21
IPC分类号： A61K39/00
CPC分类号： B82Y5/00 , A61K39/0008 , A61K2039/6093 , Y10S424/81 , Y10S530/807 , Y10S530/81 , Y10S530/813
摘要： Undesired immune responses are suppressed by administering a nonimmunogenic material which comprises one or more haptens or epitopes corresponding to the antigen which causes the undesired immune response, the number and spacing of the haptens or epitopes being insufficient to trigger an immune response but sufficient to inhibit it. Also disclosed is an improved vaccine from which low molecular weight suppressive polymer has been removed.
摘要翻译： 不期望的免疫应答通过施用非免疫原性物质来抑制，其包含一种或多种对应于抗原的半抗原或表位，其引起不希望的免疫应答，半抗原或表位的数量和间隔不足以引发免疫应答但足以抑制它 。 还公开了已经从其中除去低分子量抑制性聚合物的改进的疫苗。
-
5.发明授权Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry 失效通过施用受控化学的抗原的寡聚形式来治疗性抑制特异性免疫应答
公开(公告)号：US5370871A
公开(公告)日：1994-12-06
申请号：US49601
申请日：1993-04-20
IPC分类号： A61K39/00 , A61K39/116 , A61K39/385
CPC分类号： B82Y5/00 , A61K39/0008 , A61K2039/6093 , Y10S530/807
摘要： The present invention relates to a vaccine derived from a bacterial or virus product that initially comprises a mixture of polymers of varying molecular weights. The vaccine contains an immunogenically effective polymer comprising T-cell-independent antigen as the effective immunizing agent. The vaccine is free of low molecular weight immunosuppressive antigen-containing polymer as a result of processing of the bacterial or virus product mixture.
摘要翻译： 本发明涉及源自细菌或病毒产物的疫苗，其最初包含不同分子量的聚合物的混合物。 该疫苗含有包含与T细胞无关的抗原作为有效免疫剂的免疫原性有效的聚合物。 由于细菌或病毒产物混合物的加工，疫苗不含低分子量免疫抑制抗原的聚合物。
-
公开(公告)号：US07083959B2
公开(公告)日：2006-08-01
申请号：US09757774
申请日：2001-01-09
IPC分类号： A61K39/00
CPC分类号： B82Y5/00 , A61K39/0008 , A61K47/58 , A61K47/643 , A61K47/6951 , A61K2039/6093
摘要： The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises: i) preparing a construct comprising at least one discrete antigenically recognizable moiety corresponding to an antigenic determinant of an antigen causing the undesired immune response bound to a pharmacologically acceptable carrier wherein the number of the moieties bound to the carrier and the spacing of the moieties on the carrier are such that the construct does not elicit an immune response to the moieties but does directly compete with the antigen for receptors on an immunocompetent cell that recognizes the determinant, and thereby the construct specifically suppresses the undesired immune response; and ii) administering the construct to the mammal in an amount such that suppression of the undesired immune response is effected. The invention further relates to constructs suitable for use in the above method and to methods of making same.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.036 秒)
